reports
NovaBay Pharmaceuticals’ Avenova® Warm Eye Compress for the Relief of ...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- . (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on and on . This new, reusable heated eye compress is designed to relieve the symptoms associated with blepharitis, dry eye disease, meibomian gland disease, styes and chalazion, and is a companion product to Avenova, NovaBay’s premier antimicrobial lid and lash spray. This press release features multimedia. View the full release here: Avenova Warm Eye Compress (Graphic: Business Wire) “Most ...
Ra Medical Systems to Participate in Upcoming Virtual Investment Confe...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in two upcoming virtual investment conferences: 33rd Annual Roth Conference being held March 15-17, 2021. Ra Medical will hold virtual investor meetings. Investors interested in arranging a meeting should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available . Maxim 2021 Eme...
NovaBay CEO Issues Letter to Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals (NYSE American: NBY) issued the following Letter to Stockholders: To My Fellow Stockholders: NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: ®, the premier antimicrobial lid and lash spray, and , a breakthrough product that marked our entry into a new beauty category late last year. I’m excited to announce that we will soon expand consumer access to both products to brick-and-mortar retail stores. Avenova will be available at CVS stores, one of the nation’s larges...
NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Plac...
NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain non-U.S. institutional accredited investors providing for the purchase and sale, in a private placement, of (i) the Company’s preferred stock automatically co...
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered D...
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 mill...
NovaBay Pharmaceuticals Receives Notification of Noncompliance with Ad...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces receipt of a letter from NYSE American LLC (“NYSE American” or the “Exchange”) on September 14, 2017 stating that it is not in compliance with the continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (“Company Guide”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fisca...
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Glo...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chief Financial Officer Jack McGovern is scheduled to present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, 2017, at 2:10 p.m. Eastern time (11:10 a.m. Pacific time). The conference is being held at the New York Palace Hotel in New Y...
NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and six months ended June 30, 2017 and provides a business update. “We had record Avenova unit volume through the pharmacy channel during the second quarter, along with an 80% increase in revenue through this channel over the prior year. Our planned shift of sal...
NovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces that it will report 2017 second quarter financial results after market close on Thursday, August 10. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. ...
NovaBay Pharmaceuticals Announces CFO Transition
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a specialty pharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces that Jack McGovern will join the company as Chief Financial Officer as of July 17, 2017. Current CFO Thomas (Tom) Paulson, a 40-year healthcare finance veteran, will continue with NovaBay through his retirement at the end of the year and will lead NovaBay’s annual strategic planning process, o...
NovaBay Pharmaceuticals Joins the Russell Microcap Index
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that it has joined the Russell Microcap® Index. Each June, the Russell Microcap Index is realigned and recalibrated to reflect market changes during the past year with membership primarily determined by objective, market-capitalization rankings and style attributes. Russell indexes are widely us...
NovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitati...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that management is scheduled to present a corporate overview at the 7th Annual LD Micro Invitational Conference on Tuesday, June 6, 2017, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time). The conference is being held at Luxe Sunset Boulevard Hotel in Los Angeles. A live webcast and replay wil...
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on May 16, 2017, stating that it is not in compliance with the continued listing standards (requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years) as set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide (“Company Guide”). In order to ...
NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focused on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, reports financial results for the three months ended March 31, 2017 and provides a business update. “Avenova product sales for the quarter increased 165% over the prior year on record unit volume from our higher-margin prescription ophthalmology channel as we continued the effective implementatio...
NovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on ...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 first quarter financial results after market close on Thursday, May 11. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. DATE: ...
NovaBay Pharmaceuticals Reports 2016 Full Year and Fourth Quarter Fina...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2016 and provides 2017 financial guidance. “We made major strides in a dramatic turnaround at NovaBay in 2016 with Avenova sales increasing 175% while we narrowed our operating loss by nearly half versus the prior year, all...
NovaBay Pharmaceuticals to Hold 2016 Fourth Quarter and Full Year Conf...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2016 fourth quarter and full year financial results after market close on Thursday, March 23. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. DATE: ...
NovaBay Pharmaceuticals to Present Features and Benefits of the intell...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a pharmaceutical company focusing on commercializing its Avenova® lid and lash hygiene in the domestic eye care market, today announced that it has been invited to present information about its innovative intelli-Case™ for use with hydrogen peroxide to safely disinfect contact lenses at the U.S. Food and Drug Administration’s (FDA) Ophthalmic Devices Panel Advisory Meeting on March 17, 2017 in Gaithersburg, MD. The FDA meeting will specificall...
NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chairman, President and CEO Mark M. Sieczkarek is scheduled to present a corporate overview at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif. ...
NovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Qua...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Avenova sales for the fourth quarter of 2016 are expected to exceed $3.8 million, an increase of more than 146% over the prior year and up at least 26% from the third quarter of 2016. Total revenue for the full year of 2016 is expected to top $11.8 million, up more than 171% from 2015. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.